BRIEF-Thrombogenics Initiates Phase 2 Clinical Study For Treatment Of Diabetic Macular Edema

April 27 (Reuters) – THROMBOGENICS NV:

* THROMBOGENICS INITIATES PHASE 2 CLINICAL STUDY EVALUATING ANTI-PLGF (THR-317) IN COMBINATION WITH ANTI-VEGF (RANIBIZUMAB) FOR TREATMENT OF DIABETIC MACULAR EDEMA (DME)

* INITIAL RESULTS FROM THR-317-002 STUDY ARE ANTICIPATED IN Q3 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)



Learn More about best forex signals provider

What do you think?

0 points
Upvote Downvote

Total votes: 0

Upvotes: 0

Upvotes percentage: 0.000000%

Downvotes: 0

Downvotes percentage: 0.000000%

China’s Baidu tops profit estimates on advertising growth, shares jump

Alvean signs long-term raw sugar contract with Al Khaleej